Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

LAG-3/MHCII Blockade Bioassay, Propagation Model

Instructions for Use of Product(s)

Literature # TM571

The LAG-3/MHCII Blockade Bioassay is a bioluminescent cell-based assay that measures potency and stability of antibodies and other biologics designed to block the interaction of LAG-3 with its ligand, MHCII. LAG-3, also known as CD223, is an immune checkpoint receptor expressed on activated CD4+ and CD8+ T cells and natural killer (NK) cells. LAG-3 plays a critical role in regulating immune responses to tumor antigens and autoantigens. Engagement of LAG-3 by its best characterized ligand, major histocompatibility complex II (MHCII), inhibits TCR signaling, cytokine production and proliferation of activated T cells. Therapeutic antibodies designed to block the LAG-3/MHCII interaction show promising results in clinical trials for the treatment of a variety of cancers.

The LAG-3/MHCII Blockade Bioassay, Propagation Model (Cat.# JA1112) is a bioluminescent cell-based assay that measures the potency and stability of antibodies and biologics targeting LAG-3/MHCII and overcomes the limitations of existing assays. The LAG-3 Effector Cells and MHCII APC Cells are provided in a Cell Propagation Model (CPM) format, which includes cryopreserved cells that can be thawed, propagated and banked for long-term use (also offered in a thaw-and-use format; Cat.# JA1111, JA1115).

Printed in USA 7/19.